


## Etoprozine dihydrochloride

## Chemical Properties

|                   |   |
|-------------------|---|
| CAS No. :         | 143485-51-2   |
| Formula:          | C <sub>12</sub> H <sub>18</sub> Cl <sub>2</sub> N <sub>2</sub> O <sub>2</sub>                                       |
| Molecular Weight: | 293.19  |
| Storage:          | Powder: -20°C for 3 years   In solvent: -80°C for 1 year<br>Actual storage temperature shall be subject to the COA. |



## Biological Description

|               |  |
|---------------|--|
| Description   | Etoprozine dihydrochloride is a drug that had previously been developed for aggression, has recently been investigated for L-DOPA-induced dyskinesia in animal models of Parkinson's disease (PD) and in dyskinetic PD patients. |
| Targets(IC50) | Others,5-HT Receptor   |
| In vitro      | In the elevated plus maze etoprozine increased anxiety-like behavior. On the other hand, it induced a clear-cut anxiolytic effect in context fear conditioning test starting at ca. 0.3 mg/kg[1]                                 |

## Solubility Information

|            |   |
|------------|---|
| Solubility | DMSO: 10 mg/mL (34.11 mM),Sonication is recommended.<br>(< 1 mg/ml refers to the product slightly soluble or insoluble) |
|------------|---|

## Preparing Stock Solutions

|       | 1mg       | 5mg        | 10mg       |
|-------|-----------|------------|------------|
| 1 mM  | 3.4108 mL | 17.0538 mL | 34.1076 mL |
| 5 mM  | 0.6822 mL | 3.4108 mL  | 6.8215 mL  |
| 10 mM | 0.3411 mL | 1.7054 mL  | 3.4108 mL  |
| 50 mM | 0.0682 mL | 0.3411 mL  | 0.6822 mL  |

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

### Reference

Gravius A , Dekundy A , Vanaga A , et al. Further pharmacological characterization of eltoprazine: Focus on its anxiolytic, anorexic, and adverse-effect potential[[J](#)]. Acta neurobiologiae experimentalis, 2017, 77(1):77-85.

Keywood, Charlotte, Widner, et al. Eltoprazine counteracts l-DOPA-induced dyskinesias in Parkinson's disease: a dose-finding study[[J](#)]. Brain: A journal of neurology, 2015.

**Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins**

This product is for Research Use Only· Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E\_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481